Kura Oncology (KURA): Positive Phase II Data on tipifarnib - Oppenheimer

August 11, 2016 8:14 AM EDT
Get Alerts KURA Hot Sheet
Price: $5.35 +0.94%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 20 | Down: 15 | New: 18
Trade KURA Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Oppenheimer analyst, Michelle Gibson, reiterated her Outperform rating on shares of Kura Oncology (NASDAQ: KURA) after the company announced positive topline results from a Phase 2 study of tipifarnib in advanced HRAS-mutant solid tumors. In the cohort comprising patients with non-hematologic malignancies other than thyroid cancer (n=11), two PRs were observed, both in patients with head and neck squamous cell carcinomas ("H&N", n=3). Kura will now begin enrolling an additional seven patients into the cohort, per trial protocol.

The analyst stated "We view this data as validating Kura's HRAS hypothesis for tipifarnib as a single-agent to inhibit HRAS-mediated MAPK-activation. Follow-up data is expected in 2017 (potentially ASCO), and we will be looking for further clarity on HRAS' role in these tumors, including as a driver-oncogene. We note, however, that tipifarnib's mechanism in HRAS is distinct from other indications (CMML, PTCL, MDS) being evaluated".

No change to the price target of $16.00

For an analyst ratings summary and ratings history on Kura Oncology click here. For more ratings news on Kura Oncology click here.

Shares of Kura Oncology closed at $4.36 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View, FDA

Add Your Comment